BCS II waiver approach [Dissolution / BCS / IVIVC]

posted by yuvaneshwari – India, 2019-01-23 05:09 (873 d 21:30 ago) – Posting: # 19801
Views: 2,310

Dear All,

Drug compound is BCS-II [dosage form is solution filled in capsule], and objective is to formulate with Q1 & Q2 sameness to that of Reference. Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

In the above scenario, can we consider for BCS based waiver approach ?

Complete thread:

Activity
 Admin contact
21,518 posts in 4,498 threads, 1,524 registered users;
online 23 (0 registered, 23 guests [including 3 identified bots]).
Forum time: Tuesday 02:39 UTC (Europe/Vienna)

I suppose it is tempting, if the only tool you have is a hammer,
to treat everything as if it were a nail.    Abraham Maslow

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5